📰 Arnaud Delepine News
Page 4 - Arnaud Delepine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Arnaud Delepine. Real-time updates on events, politics, business and more.
December 1, 2021
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates Sanofi confirms Vaccines mid-term guidance
December 1, 2021
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated
December 1, 2021
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates Sanofi confirms Vaccines mid-term... | December 1, 2021
November 30, 2021
/PRNewswire/ -- In its continuing efforts to support gender equity in the workplace, Sanofi is offering all employees worldwide 14 weeks of paid parental leave...
October 25, 2021
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2...
October 22, 2021
Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Pivotal
October 20, 2021
Investegate announcements from Sanofi, FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
October 20, 2021
FDA expands approval of Dupixent (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma Dupixent is the only biologic medicine to improve lung function in children
October 13, 2021
Investegate announcements from Sanofi, New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 
October 13, 2021
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib